BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ziv E, Zhang Y, Kelly L, Nikolovski I, Boas FE, Erinjeri JP, Cai L, Petre EN, Brody LA, Covey AM, Getrajdman G, Harding JJ, Sofocleous C, Abou-Alfa GK, Solomon SB, Brown KT, Yarmohammadi H. NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation. Radiology 2020;297:225-34. [PMID: 32780006 DOI: 10.1148/radiol.2020200201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Haque E, Śmiech M, Łuczyńska K, Bouchard MF, Viger R, Kono H, Pierzchała M, Taniguchi H. NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines. Int J Mol Sci 2021;22:5296. [PMID: 34069882 DOI: 10.3390/ijms22105296] [Reference Citation Analysis]
2 Lin YM, Taiji R, Calandri M, Odisio BC. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Curr Oncol Rep 2021;23:67. [PMID: 33855606 DOI: 10.1007/s11912-021-01056-4] [Reference Citation Analysis]
3 Arora S, Catania R, Borhani A, Horvat N, Fowler K, Harmath C. HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy. Abdom Radiol (NY) 2021;46:3686-97. [PMID: 34195886 DOI: 10.1007/s00261-021-03192-8] [Reference Citation Analysis]
4 Wu BK, Chen QH, Pan D, Chang B, Sang LX. A novel therapeutic strategy for hepatocellular carcinoma: Immunomodulatory mechanisms of selenium and/or selenoproteins on a shift towards anti-cancer. Int Immunopharmacol 2021;96:107790. [PMID: 34162153 DOI: 10.1016/j.intimp.2021.107790] [Reference Citation Analysis]